Literature DB >> 1473963

Assessment of complement activation in vivo.

M Oppermann1, U Höpken, O Götze.   

Abstract

Hemolytic assays that measure the functional integrity of the complement system and the quantitation of individual components by immunochemical techniques have been widely used in the past for the assessment of in vivo complement activation. However, the complement system comprises a large number of interacting serum proteins which are subject to independent synthetic and catabolic processes. The fact that complement proteins are rapidly metabolized under in vivo conditions adds to the complexity of complement analysis. Assays that are based on monoclonal antibodies with specificities for activation-dependent neoepitopes now allow the direct determination of complement fragments in plasma. These methods are superior to the quantitation of native proteins. Several parameters that differentially affect the generation or the catabolism of individual complement activation products still have to be taken into account when elevated plasma levels of complement fragments suggest in vivo complement activation. These factors include the binding to complement fragment receptors, the degradation by serum proteases and renal or hepatic clearance. An accurate estimation of complement activation in vivo requires the simultaneous determination of both the native components and the activation products.

Mesh:

Substances:

Year:  1992        PMID: 1473963     DOI: 10.1016/0162-3109(92)90018-8

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  3 in total

Review 1.  Clinical utility of complement assessment.

Authors:  A E Ahmed; J B Peter
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

2.  Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.

Authors:  M Oppermann; O Götze
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

3.  Systemic complement activation in age-related macular degeneration.

Authors:  Hendrik P N Scholl; Peter Charbel Issa; Maja Walier; Stefanie Janzer; Beatrix Pollok-Kopp; Florian Börncke; Lars G Fritsche; Ngaihang V Chong; Rolf Fimmers; Thomas Wienker; Frank G Holz; Bernhard H F Weber; Martin Oppermann
Journal:  PLoS One       Date:  2008-07-02       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.